Sam Brusco, Associate Editor05.28.24
Terumo Cardiovascular has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its CDI OneView Monitoring system.
The next-gen CDI Systems platform offers visibility of key parameters during pulmonary bypass surgery. It measures or displays up to 22 parameters. The newest of these are measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2).
Terumo said the new features and functions were influenced by perfusionist input from leading global cardiovascular institutions. In response to healthcare providers’ needs, the new system has real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters.
Independently published and reviewed clinical research indicates maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury.
"The world's leading cardiac centers have trusted CDI Systems for over 30 years. With the launch of the new CDI OneView System, Terumo Cardiovascular continues to bring value and enhanced patient care to healthcare providers and critically ill cardiac patients," said Robert DeRyke, president and CEO of Terumo Cardiovascular. "The CDI OneView System technology is the latest extension of Terumo's commitment to delivering data-focused solutions to the perfusion community."
The next-gen CDI Systems platform offers visibility of key parameters during pulmonary bypass surgery. It measures or displays up to 22 parameters. The newest of these are measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2).
Terumo said the new features and functions were influenced by perfusionist input from leading global cardiovascular institutions. In response to healthcare providers’ needs, the new system has real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters.
Independently published and reviewed clinical research indicates maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury.
"The world's leading cardiac centers have trusted CDI Systems for over 30 years. With the launch of the new CDI OneView System, Terumo Cardiovascular continues to bring value and enhanced patient care to healthcare providers and critically ill cardiac patients," said Robert DeRyke, president and CEO of Terumo Cardiovascular. "The CDI OneView System technology is the latest extension of Terumo's commitment to delivering data-focused solutions to the perfusion community."